Latest News

(UroToday.com) Beginning with the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer including a number of novel hormonal therapies (including abiraterone acetate and enzalutamide), second-line chemotherapy (cabazitaxel), bone-targeting agents (radium-223) and other targeted agents (including olaparib, […]

Recent studies in metastatic bladder cancer suggest an overall survival benefit from treating the primary tumor.1 Upper tract urothelial cancer has similar biology to bladder cancer and nephroureterectomy has a lower complication rate; we, therefore, hypothesized that high-intensity local treatment for metastatic upper tract urothelial carcinoma (UTUC) would also be associated with improved overall survival. […]

(UroToday.com) While there have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years, these studies have focused on patients with clear cell histology. As a result, there have been little direct data to guide care for patients with non-clear cell histologies and we have had to […]

(UroToday.com) There have been transformational changes in systemic treatment for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches.

(UroToday.com) Following three presentations regarding novel treatment approaches for patients with advanced non-clear cell renal cell carcinoma (nccRCC) in the Kidney and Bladder Poster Discussion session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Deepak Kilari provided a discussant overview of these data and the rapidly moving disease space of non-clear cell […]

(UroToday.com) In this presentation, Dr. Brian Rini presented 42-month follow-up data from the KEYNOTE-426 trial of pembrolizumab in combination with axitinib as first-line therapy for clear cell renal cell carcinoma (ccRCC). The first interim analysis of this combination, published in 20191 showed a statistically significant improvement in overall survival and progression-free survival relative to sunitinib. Subsequent follow-up […]

(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the last 10 years. While there are many available treatment options, to date, we have been unable to widely operationalize rationale treatment selection in this disease space.

(UroToday.com) There have been transformational changes in first-line therapy for patients with metastatic renal cell carcinoma (mRCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition (nivolumab and ipilimumab) to the forefront, subsequent studies have examined combinations of […]

(UroToday.com) There have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition to the forefront, subsequent studies have examined combinations of immune checkpoint inhibitors […]

(UroToday.com) Following androgen deprivation therapy (ADT) which was introduced decades prior, the TAX-327 trial of docetaxel for patients with metastatic castration-resistant prostate cancer was the first to demonstrate a survival advantage for systemic treatment in prostate cancer. Since then, docetaxel has proven survival benefit for men with metastatic castration-sensitive disease. However, docetaxel requires the non-ionic surfactant […]